苑东生物(688513.SH)：EP-0226 片I期临床试验完成首例受试者给药

Core Viewpoint - Yuan Dong Biotech (688513.SH) has initiated Phase I clinical trials for its innovative drug EP-0226, developed in collaboration with the Shanghai Institute of Materia Medica and Zhongke Zhongshan Drug Innovation Research Institute, aimed at treating neuropathic pain [1] Group 1: Drug Development - EP-0226 is a novel calcium channel (Cav2.2) modulator designed to treat neuropathic pain by binding to the calcium channel α2δ subunit, reducing calcium influx in neurons, and consequently decreasing the release of excitatory neurotransmitters such as glutamate and norepinephrine [1] - Preclinical studies indicate that EP-0226 demonstrates superior target selectivity, analgesic activity, and efficacy compared to the approved drug pregabalin, with good safety profiles, potentially offering a new safe and effective treatment option for patients with neuropathic pain [1]